Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 6/20 | 0.43 |
| ▸ | NOS1 | P29475 | 5/20 | 0.43 |
| ▸ | NOS3 | P29474 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | OTC | P00480 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 2/20 | 0.42 |
| ▸ | ANPEP | P15144 | 3/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 3/20 | 0.42 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10187383 | 0.91 | OTC (0.53) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL10063628 | 0.89 | GSR (0.48) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL686695 | 0.89 | GSR (0.48) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL6579587 | 0.89 | GSR (0.48) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL19405258 | 0.88 | NOS2 (0.49) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL19970447 | 0.85 | OTC (0.44) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL19970446 | 0.85 | OTC (0.44) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL14645019 | 0.85 | GSR (0.43) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL12520125 | 0.85 | NOS2 (0.46) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL14845859 | 0.84 | DPP7 (0.55) | NOS2NOS1NOS3MEN1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | AMBRX, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230226152-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | AMBRX, INC. | 2023-07-20 | — | — | US | disclosed |
| US-9962450-B2 | Method of treating heart failure with modified relaxin polypeptides | AMBRX, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170226178-A1 | THERAPEUTIC USES OF MODIFIED RELAXIN POLYPEPTIDES | AMBRX, INC. | 2017-08-10 | — | — | US | disclosed |
| US-9567386-B2 | Therapeutic uses of modified relaxin polypeptides | AMBRX, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20170035897-A1 | Modified Relaxin Polypeptides and Their Uses | AMBRX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9517273-B2 | Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids | AMBRX, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20120046229-A1 | MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120041180-A1 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses | AMBRX, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110294161-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110288279-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110207914-A1 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses | AMBRX, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110178029-A1 | Modified Human Apolipoprotein A-1 and Their Uses | AMBRX, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110172401-A1 | Modified FGF-21 Polypeptides and Their Uses | AMBRX, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110124880-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110118451-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118501-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178029-A1 | Modified Human Apolipoprotein A-1 and Their Uses | APOB, APOL1, HDLBP | NOS2 4258/4885NOS1 3493/4885NOS3 4279/4885 |
| US-20110288279-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DAO, DNPEP | NOS2 21/4885NOS1 40/4885NOS3 25/4885 |
| US-20230226152-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | IL2, IL2RA, TAP2 | NOS2 1049/4885NOS1 4161/4885NOS3 3388/4885 |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | NOS2 1667/4885NOS1 2210/4885NOS3 2480/4885 |
| US-20110118501-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DAO, DNPEP | NOS2 21/4885NOS1 40/4885NOS3 25/4885 |
| US-20120041180-A1 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses | FGB, FCGR3B, FCGR2A | NOS2 3197/4885NOS1 3630/4885NOS3 2542/4885 |
| US-20120046229-A1 | MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES | RXFP1, RXFP2, RXFP4 | NOS2 1488/4885NOS1 2469/4885NOS3 1453/4885 |
| US-20110172401-A1 | Modified FGF-21 Polypeptides and Their Uses | FGF2, FGF1, FGF23 | NOS2 2852/4885NOS1 3622/4885NOS3 3395/4885 |
| US-20110124880-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DAO, DNPEP | NOS2 21/4885NOS1 40/4885NOS3 25/4885 |
| US-20110118451-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DAO, DNPEP | NOS2 21/4885NOS1 40/4885NOS3 25/4885 |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | NOS2 4241/4885NOS1 4297/4885NOS3 3906/4885 |
| US-20170035897-A1 | Modified Relaxin Polypeptides and Their Uses | RXFP1, RXFP2, RXFP4 | NOS2 1488/4885NOS1 2469/4885NOS3 1453/4885 |
| US-20110207914-A1 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses | FGB, FCGR3B, FCGR2A | NOS2 3197/4885NOS1 3630/4885NOS3 2542/4885 |
| US-20170226178-A1 | THERAPEUTIC USES OF MODIFIED RELAXIN POLYPEPTIDES | RXFP1, RXFP2, RXFP3 | NOS2 359/4885NOS1 576/4885NOS3 448/4885 |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | CD63, CD74, CD99 | NOS2 2216/4885NOS1 2705/4885NOS3 2785/4885 |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | RXFP1, RXFP2, RXFP3 | NOS2 396/4885NOS1 624/4885NOS3 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.